Guggenheim raises Veracyte price target to $65
Guggenheim analyst Subbu Nambi maintained a Buy rating on Veracyte (NASDAQ: VCYT) and raised the price target to $65 from $45, indicating a positive outlook.
*this image is generated using AI for illustrative purposes only.
Guggenheim analyst Subbu Nambi has maintained a Buy rating on Veracyte (NASDAQ: VCYT) and raised the price target to $65 from $45. The adjustment reflects an updated outlook on the company's stock performance.
Rating and Price Target Details
The revised price target represents a significant increase from the previous level. The following table outlines the key changes:
| Metric | Previous Value | New Value |
|---|---|---|
| Rating | Buy | Buy |
| Price Target | $45 | $65 |
What specific factors drove the 44% increase in the price target for Veracyte?
How might Veracyte's upcoming product pipeline influence its stock performance in the next year?
What are the potential risks that could hinder Veracyte from reaching the new $65 price target?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
